newsNT-300 tablets show promise in Phase III COVID-19 trial16 April 2021 | By Hannah Balfour (European Pharmaceutical Review)Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
newsPhase III trial to study NT-300 as COVID-19 treatment initiated14 August 2020 | By Victoria Rees (European Pharmaceutical Review)A Phase III trial to investigate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19 has begun.